Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

STRATA Skin Sciences (SSKN) Net Income towards Common Stockholders (2016 - 2025)

STRATA Skin Sciences' Net Income towards Common Stockholders history spans 13 years, with the latest figure at -$994000.0 for Q3 2025.

  • For Q3 2025, Net Income towards Common Stockholders rose 52.07% year-over-year to -$994000.0; the TTM value through Sep 2025 reached -$4.0 million, up 61.34%, while the annual FY2024 figure was -$10.3 million, 5.15% up from the prior year.
  • Net Income towards Common Stockholders for Q3 2025 was -$994000.0 at STRATA Skin Sciences, up from -$2.6 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $2.4 million in Q2 2021 and bottomed at -$3.9 million in Q4 2023.
  • The 5-year median for Net Income towards Common Stockholders is -$1.6 million (2025), against an average of -$1.4 million.
  • The largest YoY upside for Net Income towards Common Stockholders was 243.93% in 2021 against a maximum downside of 14123.53% in 2021.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$849000.0 in 2021, then surged by 85.87% to -$120000.0 in 2022, then crashed by 3138.33% to -$3.9 million in 2023, then soared by 131.65% to $1.2 million in 2024, then plummeted by 180.81% to -$994000.0 in 2025.
  • Per Business Quant, the three most recent readings for SSKN's Net Income towards Common Stockholders are -$994000.0 (Q3 2025), -$2.6 million (Q2 2025), and -$1.6 million (Q1 2025).